Literature DB >> 22095426

Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results.

X Yao1, M Zeng, H Wang, S Fei, S Rao, Y Ji.   

Abstract

PURPOSE: The authors sought to identify metabolic features of pancreatic carcinoma by in vivo proton magnetic resonance (MR) spectroscopy at 3 Tesla.
MATERIALS AND METHODS: Forty healthy volunteers and 40 patients with pancreatic carcinoma confirmed by histopathology underwent T2-weighted imaging for localisation of the single voxel. Respiration-triggered (1)H MR spectroscopy was used to detect metabolites in normal pancreas and cancerous tissue. All spectral data were processed with SAGE software. Unsuppressed water at 4.7 ppm was used as an internal reference to determine metabolite concentrations. Each ratio among the different peak areas was statistically evaluated between normal pancreas and pancreatic carcinoma.
RESULTS: The following five groups of spectra were detected: unsaturated fatty acids (-CH = CH-) at 5.4 ppm; residual water at 4.7 ppm; choline metabolites at 3.2 ppm; unsaturated fatty acids (-CH2-CH = CH-) or a combination of N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), glutamine, glutamate, macromolecules and unsaturated fatty acids (-CH2-CH = CH-) at 2.0 ppm and lipids at 1.3 ppm. Ratio of lipids to unsuppressed water in normal pancreas was statistically greater than that in pancreatic cancer (p=0.004). Ratio of choline to unsuppressed water in normal pancreas was statistically greater than that in pancreatic cancer (p=0.0001). Ratio of fatty acids (-CH = CH-) to lipids in normal pancreas was statistically lower than that in pancreatic cancer (p=0.006).
CONCLUSIONS: Compared with normal pancreas, pancreatic carcinoma has a higher ratio of fatty acids (-CH = CH-) to lipids and lower ratios of lipids to unsuppressed water and choline to unsuppressed water at 3T.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095426     DOI: 10.1007/s11547-011-0757-7

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  32 in total

Review 1.  Body MR imaging at 3.0 T: understanding the opportunities and challenges.

Authors:  Mara M Barth; Martin P Smith; Ivan Pedrosa; Robert E Lenkinski; Neil M Rofsky
Journal:  Radiographics       Date:  2007 Sep-Oct       Impact factor: 5.333

Review 2.  In vivo magnetic resonance spectroscopy in cancer.

Authors:  Robert J Gillies; David L Morse
Journal:  Annu Rev Biomed Eng       Date:  2005       Impact factor: 9.590

3.  The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis.

Authors:  M Murphy; A Loosemore; A G Clifton; F A Howe; A R Tate; S A Cudlip; P R Wilkins; J R Griffiths; B A Bell
Journal:  Br J Neurosurg       Date:  2002-08       Impact factor: 1.596

4.  Genomic organization, promoter activity, and expression of the human choline transporter-like protein 1.

Authors:  Zongfei Yuan; Angela Tie; Mark Tarnopolsky; Marica Bakovic
Journal:  Physiol Genomics       Date:  2006-04-11       Impact factor: 3.107

5.  Choline increases serum insulin in rat when injected intraperitoneally and augments basal and stimulated aceylcholine release from the rat minced pancreas in vitro.

Authors:  Yesim Ozarda Ilcol; M Sibel Gurun; Yavuz Taga; Ismail H Ulus
Journal:  Eur J Biochem       Date:  2003-03

6.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.

Authors:  J Kurhanewicz; D B Vigneron; H Hricak; P Narayan; P Carroll; S J Nelson
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

Review 7.  Choline and human nutrition.

Authors:  S H Zeisel; J K Blusztajn
Journal:  Annu Rev Nutr       Date:  1994       Impact factor: 11.848

8.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy.

Authors:  F A Howe; S J Barton; S A Cudlip; M Stubbs; D E Saunders; M Murphy; P Wilkins; K S Opstad; V L Doyle; M A McLean; B A Bell; J R Griffiths
Journal:  Magn Reson Med       Date:  2003-02       Impact factor: 4.668

9.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

Review 10.  Going malignant: the hypoxia-cancer connection in the prostate.

Authors:  P W Hochachka; J L Rupert; L Goldenberg; M Gleave; P Kozlowski
Journal:  Bioessays       Date:  2002-08       Impact factor: 4.345

View more
  14 in total

1.  CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation.

Authors:  Thomas W Miller; David R Soto-Pantoja; Anthony L Schwartz; John M Sipes; William G DeGraff; Lisa A Ridnour; David A Wink; David D Roberts
Journal:  J Biol Chem       Date:  2015-08-26       Impact factor: 5.157

Review 2.  Magnetic resonance imaging of pancreatitis: an update.

Authors:  Sriluxayini Manikkavasakar; Mamdoh AlObaidy; Kiran K Busireddy; Miguel Ramalho; Viragi Nilmini; Madhavi Alagiyawanna; Richard C Semelka
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 3.  Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

4.  Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.

Authors:  Shawn A Ritchie; Bassirou Chitou; Qingan Zheng; Dushmanthi Jayasinghe; Wei Jin; Asuka Mochizuki; Dayan B Goodenowe
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 5.  Morphological and functional evaluation of chronic pancreatitis with magnetic resonance imaging.

Authors:  Tine Maria Hansen; Matias Nilsson; Mikkel Gram; Jens Brøndum Frøkjær
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

6.  Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism.

Authors:  Marie-France Penet; Tariq Shah; Santosh Bharti; Balaji Krishnamachary; Dmitri Artemov; Yelena Mironchik; Flonné Wildes; Anirban Maitra; Zaver M Bhujwalla
Journal:  Clin Cancer Res       Date:  2014-11-04       Impact factor: 12.531

7.  PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis.

Authors:  Bang-Bin Chen; Yu-Wen Tien; Ming-Chu Chang; Mei-Fang Cheng; Yu-Ting Chang; Chih-Horng Wu; Xin-Jia Chen; Ting-Chun Kuo; Shih-Hung Yang; I-Lun Shih; Hong-Shiee Lai; Tiffany Ting-Fang Shih
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

8.  Role of Increased n-acetylaspartate Levels in Cancer.

Authors:  Behrouz Zand; Rebecca A Previs; Niki M Zacharias; Rajesha Rupaimoole; Takashi Mitamura; Archana Sidalaghatta Nagaraja; Michele Guindani; Heather J Dalton; Lifeng Yang; Joelle Baddour; Abhinav Achreja; Wei Hu; Chad V Pecot; Cristina Ivan; Sherry Y Wu; Christopher R McCullough; Kshipra M Gharpure; Einav Shoshan; Sunila Pradeep; Lingegowda S Mangala; Cristian Rodriguez-Aguayo; Ying Wang; Alpa M Nick; Michael A Davies; Guillermo Armaiz-Pena; Jinsong Liu; Susan K Lutgendorf; Keith A Baggerly; Menashe Bar Eli; Gabriel Lopez-Berestein; Deepak Nagrath; Pratip K Bhattacharya; Anil K Sood
Journal:  J Natl Cancer Inst       Date:  2016-01-26       Impact factor: 13.506

9.  HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.

Authors:  Alan S Wang; Alessia Lodi; Lee B Rivera; Jose L Izquierdo-Garcia; Matthew A Firpo; Sean J Mulvihill; Margaret A Tempero; Gabriele Bergers; Sabrina M Ronen
Journal:  NMR Biomed       Date:  2014-09-09       Impact factor: 4.044

Review 10.  Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up.

Authors:  Rushika M Perera; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2015-11-03       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.